SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is highly fragmented, with participants primarily debating political, social, and geopolitical controversies surrounding the company's namesake and his administration rather than focusing on specific financial or business catalysts. The most common themes include reactions to the U.S.-Iran conflict, ongoing trade tensions with Canada, and criticism of the company's leadership.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Investors are intensely focused on the delayed topline results of the phase 3 REGAL trial for GPS, with discussion centering on the clinical implications of the extended trial duration and whether the long-tail survival indicates superior efficacy or trial design variables. The community remains divided, with long-term investors pointing to trial management and potential buyout interest, while others express caution regarding legal investigations and the lack of official event-milestone confirmation.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as investors rotate into the nuclear energy sector, fueled by growing electricity demand from AI data centers and ongoing industry developments. While some traders remain optimistic about the company's long-term potential as a small modular reactor provider, others express frustration over the lack of near-term commercial contracts and recent financial results.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending primarily due to community optimism following strong quarterly earnings, which highlighted robust performance across its drug portfolio and increased sales guidance. Traders are also closely monitoring the company's progress on late-stage trials for its obesity drug, MariTide, as a key catalyst for future growth.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending following mixed Q1 earnings results, where a slight revenue miss was overshadowed by a robust earnings beat, strong order guidance, and sustained confidence in the company's margin expansion and platform growth. Despite the positive market reaction to the outlook, investor debate persists regarding the stock's premium valuation and the sustainability of its growth model in a challenging economic environment.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing heightened investor attention as traders speculate on potential regulatory developments and prospective ETF launches, while the community remains divided over the impact of token emissions and leadership's role in price performance. Sentiment is mixed, with some participants expressing frustration over past volatility and dilution concerns, while others view current price levels as an accumulation opportunity tied to recent institutional interest.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores is receiving attention following a fiscal first-quarter earnings report that featured a double-line beat, though shares declined as investors reacted to stagnant annual guidance and concerns regarding slowing comparable-store sales growth. The community remains divided between long-term investors highlighting the company's defensive business model and profitable convenience-store operations versus traders focused on the recent selloff and potential overvaluation.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as market participants debate the stock's valuation and outlook ahead of upcoming quarterly earnings. While some traders express bearishness regarding macro pressures on consumer spending and the stock's long-term downtrend, others identify it as an oversold opportunity driven by strong autoship retention and institutional ownership.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as traders react to a formal proposal for a native decentralized stablecoin and recent shifts in tokenomics, sparking debate over its long-term potential versus concerns about persistent price declines. While some investors remain bullish on its underlying technology and staking rewards, others criticize its performance and market sentiment as fragmented.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending as traders react to a new $100 million bank guarantee that strengthens the company's liquidity and supports the acceleration of its Phase 2 expansion. While the stock has seen significant volatility, the community is divided between bullish sentiment regarding the company's production execution and ongoing skepticism from those concerned about historical price manipulation and the stock's tendency to reverse gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a marketread more...

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals has a marketread more...

Ligand Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $301.78, changing hands for $303.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

Ligand Pharmaceuticals Director Unloads 2,501 Shares  Should You Be Concerned?

Key PointsKozarich sold 2,501 common shares...

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

Key Points5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share...

Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the business's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $231.31, for a total transaction of $1,156,550.00. Following the completion of the...

Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS lessened its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,342 shares of the biotechnology compan...

HC Wainwright Brokers Increase Earnings Estimates for LGND

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Ligand Pharmaceuticals in a research note...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Equity

Neutral Sentiment

Yes, hike is locked in

No, inflation data still matters more

Fed stays on hold anyway

Too early to tell

August nonfarm payrolls surged by 162,000, nearly triple the 53,000-56,000 consensus estimate and the strongest monthly gain since March, while unemployment held steady at 4.1%, adding fuel to the case for a Federal Reserve rate hike at its September meeting. Does this jobs report cement a September rate hike? Vote and explain your reasoning in the comments.

August nonfarm payrolls surged 162,000, nearly triple estimates, while unemployment held at 4.1%. Does this cement a September rate hike?

Current Price	$288.83
Prev Close	$285.60
Open	$285.05
Dividend Yield	0.00%
50-Day Moving Average	$297.23
Beta	1.02
Avg. Volume	227,399.70
PE Ratio	30.88

52-Week High	$326.63
52-Week Low	$161.82
Market Capitalization	$5.69B
EPS (Annual)	$6.13
Price to Book	5.95
Revenue Per Employee	$5.7M

Feed

News

Sentiment

Earnings

Fundamentals

Info

LGND Fundamentals